PT  - JOURNAL ARTICLE
AU  - Junko Kurita
AU  - Tamie Sugawara
AU  - Yoshiyuki Sugishita
AU  - Yasushi Ohkusa
TI  - Excess Mortality in Suicide caused by COVID-19 in Japan
AID  - 10.1101/2021.02.13.21251670
DP  - 2021 Jan 01
TA  - medRxiv
PG  - 2021.02.13.21251670
4099  - http://medrxiv.org/content/early/2021/04/12/2021.02.13.21251670.short
4100  - http://medrxiv.org/content/early/2021/04/12/2021.02.13.21251670.full
AB  - Background Countermeasures against COVID-19 outbreak such as lockdown and voluntary restrictions against going out adversely affect human stress and economic activity. Particularly, this stress might lead to suicide.Object We examined excess mortality attributable to suicide caused by COVID-19.Method We applied the NIID model to suicide deaths from October 2009 through November, 2020 for the whole of Japan for both genders. Effects of the great earthquake that struck in eastern Japan on March 11, 2011 were incorporated into the estimation model.Results Significant excess mortality in suicide was found between July and November in 2020 for both genders. It was greater among females than among males. In total, 1599 excess cases of mortality were identified.Discussion and Conclusion Excess mortality during the four months was more than two times greater than the number of COVID-19 deaths confirmed by PCR testing. Countermeasures against COVID-19 should be chosen carefully in light of suicide effects.Competing Interest StatementThe authors have declared no competing interest.Funding StatementThe author(s) received no specific funding for this work.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:All information used for this study was published on the web site of MHLW. Therefore, no ethical issue is presented. All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesNational Institute of Infectious Diseases, Excess mortality in Japan, on October 2020. https://www.niid.go.jp/niid/ja/from-idsc/493-guidelines/10150-excess-mortality-21jan.html